TP53 and metabolic dysfunction-associated steatotic liver disease: Moreover, our analysis of human MASLD/MASH liver samples and a murine MASH model revealed elevated hepatic expression of FDXR, p53, and p21, indicating that p53-FDXR signaling is activated during MASLD progression.